CYP2C19 and myocardial infarction: A study by Megaet al. involving 1,477 acute coronary syndrome patients, with primary outcomes characterized by death from nonfatal myocardial infarct (MI), nonfatal stroke, and other cardiovascular causes, showed a significantly higher rate of LOF polymorphism (12.1% vs 8%; P = 0.01) than wild-type CYP2C19.15 For 450 days after clopidogrel therapy, similar results were reported for the rate of stent thrombosis (2.6% vs 0.8%; P = 0.02).